Comparison of c.d. spectra of Zn-insulin with Zn2+-free insulin demonstrated significant differences. It has been proposed that these differences are due to either changes in the structure of insulin monomers within aggregated insulins or the results of insulin aggregation. The effect of Zn2+ on the immunological activity of insulin indicated that the antigenic determinants of insulin were also altered. The apparent loss of immunological activity of monoiodotyrosylinsulin was demonstrated to be due to the loss of Zn2+ rather than the substitution of iodine. The immunological activity of Zn-insulin and Zn2+-free insulin was compared in both the radioimmune and immune haemolysisinhibition assays by using an identical population of antibodies and concentrations of inhibitor. Relative to Zn-insulin, Zn2+-free insulin had a markedly attenuated immunological activity in the immune haemolysis-inhibition assay, whereas in the radioimmune assay slightly greater immunological activity was observed with the Zn2+-free insulin. These observations are submitted as evidence that the removal of Zn2+ perturbs the conformation of determinants that react with antibodies operative in the immune haemolysis-inhibition assay (immune haemolysis determinants) and has a minimal effect on the conformation of determinants that react with antibodies operative in the radioimmune assay (radioimmune determinants).
Previous studies from this laboratory demonstrated that the structure of insulin in solution (Arquilla et al., 1969; Arquilla & Stanford, 1972) was similar to the structure of insulin in 2-Zn rhombohedral crystals (Adams et al., 1969; Blundell et al., 1972) .
Alterations in the structure of insulin from that delineated by X-ray crystallography resulted in decreased biological activity (Arquilla et al., 1969; Blundell et al., 1972; Gliemann & Gammeltoft, 1974) . There have been several c.d. studies (Hamlin & Arquilla, 1974; Goldman & Carpenter, 1974) that demonstrated significant differences between Zn2+-free insulin and Zn-insulin. These observations were of insulin in solution at concentrations where it is aggregated. However, insulin in circulation is at concentrations where it probably exists as a monomer (Goldman, 1971) . Influences by Zn2+ on insulin at very low concentrations would therefore be of direct interest with regard to its action and metabolism in viva.
Experiments on preparations of monoiodotyrosylinsulin initially suggested that iodine substitution caused a decrease in the immunological activity of insulin as measured by the immune haemolysisinhibition and radioimmune assays . It was subsequently demonstrated that the Vol. 175 addition of Zn2+ restored the immunological activity of purified preparations of monoiodotyrosylinsulin (Hamlin & Arquilla, 1974) .
The results of these preliminary experiments indicated that Zn2+ induced significant alterations in the tertiary structure of insulin and also affected its binding to antibodies. Experiments were therefore designed to study the effects of Zn2+ on the immunological activity of insulin at concentrations where it is thought to exist predominantly as a monomer. Two immunological systems, the immune haemolysis-inhibition assay and radioimmune assay, were used to measure the ability of antibodies to bind to different regions on the insulin molecule (Arquilla et al., 1976) .
Experimental Antisera
The insulin antiserum (A) used in the immune haemolysis experiments and the first group of immune haemolysis-inhibition experiments was a pool from ten mongrel guinea pigs. The insulin antiserum (LW4175) used to compare the reactivity of the various insulins in the inm'une haemolysisinhibition assay and the radioimnune assay was a K pool from 15 mongrel guinea pigs. In both cases the guinea pigs were immunized with 10 x recrystallized bovine Zn-insulin (Novo Industri A/S, Copenhagen, Denmark; lot 012269) and antisera prepared as previously described (Brugman & Arquilla, 1973) . The Zn2+ content of this preparation was 0.76% (equivalent to 0.6 atom of Zn2+ per molecule of insulin). It is unknown whether the Zn2+ crystals were in the 2-Zn or 4-Zn form or mixtures of both.
The lysozyme antiserum pool was prepared with 3 x recrystallized hen's egg-white lysozyme (Pentex, Kankakee, IL, U.S.A.; lot 24, code EZ1962) as the antigen. The antisera were raised in ten guinea pigs in the same manner as the insulin antisera.
Complement
The complement used in all the immune haemolysis experiments was a single pool of fresh guineapig sera from 15 animals that was adsorbed on sheep erythrocyte stroma as described in Arquilla & Finn (1963) .
Preparation of insulin and insulin derivatives
Zn2+-free insulins were prepared by chelation with EDTA (Sluyterman, 1955) , precipitation with cold acetone (Carpenter, 1958) or column chromatography (Hamlin & Arquilla, 1974) . All of these preparations had similar c.d. spectra and were indistinguishable immunologically. The Zn2+ content of several of these preparations, as measured by atomic absorption, was never greater than 1 atom of Zn2+ per 15 molecules of insulin (Elek Microanalytical Laboratories, Torrance, CA, U.S.A.).
['27I]Monoiodotyrosylinsulin and carrier-free ['25I]monoiodotyrosylinsulin were prepared by a modification (Sodoyez et al., 1975) of the method of Hamlin & Arquilla (1974) . These preparations contained 1 atom of iodine per molecule of insulin. The unchanged insulin isolated by this procedure formed a single band on polyacrylamide gels (monocomponent insulin) (Hamlin & Arquilla, 1974; Sodoyez et al., 1975) . The [2ljI]monoiodotyrosylinsulin and monocomponent insulin obtained in this manner had the same immunological activity and c.d. spectra identical with those of the Zn2+-free insulin prepared by the methods of Carpenter (1958) and Sluyterman (1955) . The carrier-free [1251]_ monoiodotyrosylinsulin used as an immunological indicator in the radioimmune assay contained approx. 25OmCi/mg (Sodoyez et al., 1975) .
The Zn-insulins used in the c.d. studies were prepared by dissolving Zn2+-free insulin in half the final volume of 0.01M-HC1, which contained the appropriate amount of ZnSO4 (reagent grade, Mallinckrodt Co., St. Louis, MO, U.S.A.) and then adjusted to the final volume with 0.22M-sodium phosphate buffer, pH7.4. The final concentration of insulin was 0.17mM in all cases. All insulin concentrations refer to insulin in its monomeric form.
The Zn-insulin used to prepare the immunological indicator (Zn-insulin-sheep-erythrocyte conjugates) in the immune haemolysis experiments was prepared by equilibrating Zn2+-free insulin at a concentration of 1.Omg/ml (A276 1.04) in 1.5 ml of 0.11 M-sodium phosphate buffer, pH7.4, with 0.01 ml of 15.7mM-ZnSO4 in deionized water. The mixture was left to incubate for 1 h in a gyratory water bath at 4°C. This insulin had the same molar ratio of Zn2+/insulin (0.6) as the insulin used to raise antibodies and was therefore considered to be homologous.
The Zn-insulin used in the first group of immune haemolysis-inhibition experiments was prepared by adding C.O1 ml of 0.523 mM-Zn2+ to 0.05 ml of 1.0mg of Zn2+-free insulin/ml and incubated for 1 h before being diluted to the appropriate concentrations with Veronal-buffered saline (Kabat & Mayer, 1961) (310-250nm) were performed by using a 1 cm optical-path-length, whereas a 0.02cm path-length was used in the far-u.v. region (250-200nm) . Immune 
haemolysis experiments
In these experiments either Zn2+-free insulin or Zn-insulin was conjugated to sheep erythrocytes with bisdiazobenzidine (Arquilla & Finn, 1965 (Arquilla et al., 1976) .
In this first group of experiments antiserum A was used at a dilution sufficient to lyse 80% of the 8.7 x 106 Zn-insulin-erythrocyte conjugates in the presence of an excess of complement (Brugman & Arquilla, 1973; Arquilla et al., 1976) .
The percentage of immunological activity was calculated from the ratio of the amount of homologous inhibitor (Zn-insulin) to the amount of heterologous inhibitor (Zn2+-free insulin) required to inhibit 50% of the immune haemolytic activity induced by the pre-selected amount of antiserum.
To compare results of the immune haemolysisinhibition assay with those from the radioimmune assay (see below), a second series of immune haemolysis-inhibition experiments was performed, which differed from those just described in three ways. The antiserum used was lot LW4175 and its initial dilution was sufficient to lyse 95 % of 8.7 x 106 Zn-insulin-erythrocyte conjugates. The Zninsulin inhibitor was diluted in VBS/albumin medium containing lOpM-ZnSO4 (approximate concentration of Zn2+ in the circulation; Underwood, 1962). These changes were necessary for effects on the two immunological assay systems to be tested with the same dilution of the same antiserum, and at a constant concentration of Zn2+.
Radioimmune assay
The radioimmune assay was a modification of the charcoal/dextran method of Herbert et al. (1965) with carrier-free [125I]monoiodotyrosylinsulin as the indicator (Arquilla et al., 1976) . The antiserum pool used was lot LW4175 at a dilution necessary to bind 32% of the ['251 ]monoiodotyrosylinsulin indicator. The near-and far-u.v. path-lengths were 1 cm and 0.02cm respectively. The ZnSO4 concentrations were: 16pM
(----), SO2M50 (-), 0.1 mM (. * . .-) and zero (---- (Fig. 1) .
The effect of Zn2+ on the c.d. spectra in the nearu.v. was reversed with EDTA (Fig. 2) . The addition of equimolar EDTA to 0.1 mM-Zn2+ resulted in a c.d. spectrum identical with that recorded for Zn2+-free insulin. EDTA added to half the molarity of the added Zn2+ yielded a spectrum comparable with that recorded for the solution containing 504uM-Zninsulin (Fig. 2 ). Effect of Zn2+ on the conformation of antigenic determinants on insulin studies by immune haemolysis and immune haemolysis inhibition
In immune haemolysis experiments approx. 7 times more antiserum was needed to haemolyse 50 % of the Zn2+-free-insulin-erythrocyte conjugates than was required to haemolyse 50% of the Zn-insulinerythrocyte conjugates (Fig. 3) .
This decreased ability of antibodies to combine with Zn2+-free-insulin-erythrocyte conjugates compared with Zn-insulin-erythrocyte conjugates is submitted as evidence that Zn2+ induces structural changes that involve the conformation of exposed antigenic determinants on insulin. As it is likely that aggregated forms of insulin cross-linked by bisdiazobenzidine were coupled to the surface of these erythrocyte preparations, the reaction of antibodies 1978 Antiserum dilution 1/640 Fig. 3 . Immune haemolysis of Zn-insulin-erythrocyte conjugates (e) and Zn2+-free-insulin-erythrocyte conjugates (0) by insulin antiserum The percentage cross-reactivity was calculated from the ratio of the amount of antiserum required to haemolyse 50% of the Zn2+-free-insulin-erythrocyte conjugates to the amount of the antiserum required to haemolyse 50°% of the homologous Zn-insulinerythrocyte conjugates. The immunological activity of Zn-insulin was considered to be 100%. The immunological activity of Zn2+-free insulin was 14.5 ± 0.9°(mean ± S.E.M.; n = 14).
with either the Zn-insulin-or Zn2+-free-insulinerythrocyte conjugates involved determinants on the surface of aggregated insulin complexes. Studies in which albumin was conjugated to erythrocytes by bisdiazobenzidine have demonstrated that multiplefunctional groups on the albumin molecule were involved in the conjugation (Gelewitz et al., 1954; Tabachnick & Sobotka, 19,60) . It is therefore reasonable to assume that the insulin aggregates conjugated to the erythrocytes were oriented in many different ways. Determinants buried because of insulin aggregation, such as the residues involved in dimer and hexamer formation, were probably not accessible to antibodies, whereas exposed determinants on the surface of the hexamer or dimer would be accessible. The relatively larger number of antibodies necessary to lyse Zn2+-free-insulinerythrocyte conjugates is evidence that the removal of Zn2+ perturbs the determinants accessible to antibodies in the immune haemolysis reaction.
The effects induced by Zn2+ measured by c.d. spectroscopy and immune haemolysis were observed at insulin concentrations of 167AM. At this concentration, Zn-insulin is aggregated as hexamers (Arquilla et al., 1969) . Of particular interest with respect to insulin action in vivo is the possibility that Zn2+ can induce structural changes at very low concentrations of insulin. Immune haemolysisinhibition experiments were therefore performed with Zn-insulin and Zn2+-free insulin as inhibitors at concentrations ranging from 1.74nm to 1.74,uM. In these experiments less Zn-insulin was required Vol. 175 to inhibit haemolysis by antibodies than Zn2+-free ins6lin (Fig. 4) . These results further substantiate the theory that removal of Zn2+ perturbs those determinants on insulin that interact with antibodies operative in the immune haemolysis-inhibition assay. In addition, this effect persists at concentrations where insulin is predominantly a monomer. In the absence of Zn2+, insulin dimers begin to form at concentrations of 8.33AM (Goldman, 1971) . Preliminary data from Goldman (1971) suggest that Zn-insulin at concentrations of 16.7,UM exists mainly in the dimer form. It is not known whether Zninsulin exists as a dimer at the significantly lower concentration of Zn-insulin (43.5nM) used to inhibit 50% of the antibodies in the immune haemolysisinhibition assay.
Possible non-specific effects that Zn2+ might have on the immune haemolysis assays were tested in a system that was independent of insulin and insulin antibodies. This system consisted of lysozyme as the antigen and pooled guinea-pig lysozyme antisera as the source of antibodies. The Zn-lysozymeerythrocyte conjugates and Zn2+-free-lysozymeerythrocyte conjugates were prepared in the same manner as the Zn-insulin-and Zn2+-free-insulinerythrocyte conjugates. No significant difference in the ability of the lysozyme antibodies to haemolyse either Zn2+-free-lysozyme-erythrocyte or Zn-lysozyme-erythrocyte conjugates was observed. We therefore feel that the results noted with the immune haemolysis and the immune haemolysis-inhibition experiments were due to alterations in the conformation of the antigenic determinants on insulin instead of possible non-specific effects. and Zn2+-free insulin (0) The percentage cross-reactivity was calculated from the ratio of the amount of homologous inhibitor (Zn-insulin) to the amount of heterologous inhibitor (Zn2+-free insulin) required to inhibit 50% of the immune haemolytic activity induced by a given dilution of antiserum. The immunological activity of Zn-insulin was 100% by definition. The immunological activity of Zn2+-free insulin was measured as 3.7 ± 0.86% (mean ± S.E.M.; n = 6). (Hamlin & Arquilla, 1974) . Preliminary studies at that time indicated that the immunological activity of Zn2+-free insulin was significantly decreased in comparison with Zninsulin in the immune haemolysis-inhibition assay. Experiments were therefore designed to study the effects of Zn2+ on the immun6logical activity of both insulin and monoiodotyrosylinsulin by immune haemolysis inhibition.
The results of these experiments are shown in Fig. 5 determinants on insulin that are operative in the immune haemolysis-inhibition assay. Removal of Zn2+, however, does significantly alter these determinants. Previous reports from our laboratory proposed that iodine substitution altered the conformation of antigenic determinants involving the A-chain tyrosine residues at A-14 and A-19. Our present observations demonstrate that the previous results were due to the effects of Zn2+ and not as a result of iodine substitution.
Effect ofZn2+ on antigenic determinants of insulin as measured by immune haemolysis-inhibition and radioimmune assays Antibody populations directed toward determinants involved in the radioimmune assay can be distinguished from determinants involved in the immune haemolysis-inhibition assay (Arquilla et al., 1976) . To determine whether Zn2+ alters the radioimmune determinants to a greater degree than the immune haemolysis determinants or vice versa, Zn2+-free insulin was compared with Zn-insulin, in each of the assays. The same dilution of a single antiserum and the same concentrations of inhibitor were used in each of these assay systems. In all cases Zn-insulin (homologous antigen) was considered to have 100% immunological activity.
In the immune haemolysis-inhibition assay, Zninsulin (100%) was a much more effective inhibitor than Zn2+-free insulin (0.86% S.E.M. ± 0.08 %; Fig. 6 ). On the other hand, in the radioimmune assay, Zn2+-free insulin was a slightly more effective inhibitor (125.21 % S.E.M. + 10.38 %) than Zn-insulin (100%) (Fig. 7) . Immunological activities of insulin and Zn-insulin complexes were determined at a point where 50% of the antibodies were inhibited 1978 of Zn-insulin (a) and Zn2+-free insulin (0) by radioimmune assay C0 represents the number of counts in the supernatant in the absence of insulin or any inhibiting material. Cl represents the radioactivity in the supernatant in the presence of Zn2+-free insulin or Zn-insulin. The immunological activity was calculated from the ratio of pg of Zn-insulin to pg of monocomponent insulin needed for C0/C1 = 2. Zn-insulin was assumed to be 100% active (correlation coefficient = 0.9952 for Zn-insulin, and 0.9853 for Zn2+-free insulin).
and paired-data analysis of four experiments demonstrated that the immunological activity of Zn2+-free insulin is greater than that of Zn-insulin in the radioimmune assay (0.05 < P < 0.1 by Student's t test). The radioimmune assay and immune haemolysis-inhibition assay experiments were performed with identical concentrations of the same insulin antiserum and inhibitor. We are therefore confident that comparison of the immunological activities in the respective assays is valid.
Zn2+-free insulin reacted with antibodies operative in the immune haemolysis-inhibition assay to a lesser degree than did Zn-insulin, indicating that the absence of Zn2+ significantly altered the immune haemolysis determinants. In contrast, Zn2+-free insulin reacted with antibodies operative in the radioimmune assay to a slightly greater degree than did Zn-insulin, indicating that in the absence of Zn2+ the radioimmune determinants become more reactive. The divergence of the regression curves for Zn-insulin and Zn2+-free insulin in the radioimmune assay (Fig. 7) demonstrates that the increased reactivity of Zn2+-free insulin was greater at high inhibitor concentrations.
Discussion
Our c.d. studies confirmed and extended earlier findings that Zn2+ induced changes in the c.d. spectra of insulin (Hamlin & Arquilla, 1974; Vol. 175 Goldman & Carpenter, 1974; Strickland & Mercola, 1976) . The c.d. changes observed in the near-u.v. region induced by Zn2+ involved the environment of the tyrosine residues (Strickland & Mercola, 1976) . The changes seen in the far-u.v. region at 222nm involved the fl-structure (Quadrifoglio & Urry, 1968) , a feature of the dimer. The changes at 208nm involved the a-helix (B1O-B19), a feature of the monomer (Ettinger & Timasheff, 1971; Goldman & Carpenter, 1974) . The c.d. differences could therefore be explained by Zn2+-induced changes in the conformation of the monomer and/or dimer, changes in the state of aggregation, or a combination of changes that involve conformation and aggregation.
Antisera used in these experiments were raised in guinea pigs against 10 x recrystallized Zn-insulin. This insulin preparation contained 0.76 % Zn2+, equivalent to 0.6 atom of Zn2+ per molecule of insulin. It is not known whether the Zn2+ crystals were in the 2-Zn or 4-Zn form or a mixture of both. It is reasonable to assume that most of the antibodies directed against insulin were primarily against the Zn2+ form, as it was present in the material used as the antigen (Freunds adjuvant). Consequently, the Zn2+-free insulin used in the experiments was considered to be the heterologous antigen and the Zn-insulin the homologous antigen.
The slight but significantly increased immunological reactivity of Zn2+-free insulin in the radioimmune assay, observed at the higher concentrations of inhibitors, could be explained by the presence of antibodies directed against determinants involving the dimer region (Brugman & Arquilla, 1973; Arquilla et al., 1976) . The relative immunological reactivity between Zn2+-free insulin and Zn-insulin was negligible at the lower concentrations of inhibitor. This suggested that, with increasing concentrations of inhibitor, Zn-insulin dimers were formed, decreasing the accessibility of radioimmune determinants involving the dimer site. Because the differences between Zn2+-free and Zn-insulin in the radioimmune assay were slight, it is likely that there were relatively few antibodies involved in this proposed interaction. Probably there were other antibodies directed against determinants operative in the radioimmune assay, which were also operative in the immune haemolysis assay, such as the A-chain a-loop (A8--A10). Berson & Yalow (1959) and Grodsky et al. (1959) observed radioimmune-assay differences in the immunological reactivity of various mammalian insulins that differed only in this region. There were, in addition, determinants on the A-chain solvent surface that were operative in the immune haemolysis assay, but which were not expressed to a significant degree in the radioimmune assay. These determinants were markedly perturbed in the absence of Zn2+.
The most pronounced effect of Zn2+ was observed when Zn2+-free insulin was treated with antibodies in the direct immune haemolysis and immune haemolysis-inhibition assays. These assays measured antibody-insulin interactions on an insoluble matrix (erythrocytes) and in solution respectively. The attenuated immunological activity of Zn2+-free insulin in both of these systems reinforced the interpretation that removal of Zn2+ significantly perturbed the antigenic determinants on insulin.
Previous work from our laboratory (Brugman & Arquilla, 1973; Arquilla et al., 1976) indicated that determinants operative in the immune haemolysis assay involved the solvent-exposed portions of insulin as it exists in 2-Zn crystals. This portion of insulin is comprised predominantly of the surface A-chain residues. Therefore it follows that the attenuated behaviour of Zn2+-free insulin in the immune haemolysis and immune haemolysisinhibition experiments (Figs. 3, 4 and 6) were due to alterations of this portion of the A-chain. However, the interaction that caused these structural alterations of the A-chain determinants are not readily explained by our knowledge of the structure of insulin, as it is known in either 2-Zn crystals or 4-Zn crystals (G. Dodson, personal communications).
The observed immunological changes may possibly be explained by Zn2+-induced aggregation. The reports by Goldman & Carpenter (1974) and Blundell et al. (1972) , however, indicated that the most favourable concentration for dimer formation in the absence of metals occurs at insulin concentrations of 50g/ml (8.33AM). In the immune haemolysis-inhibition assay and radioimmune assay experiments, insulin inhibitors were used at concentrations ranging from 1.74nM to 1.74,uM. Less than 1 % dimer formation would be expected for Zn2+-free insulin at the higher concentration used. It can be argued that Zn-insulin crystals remain aggregated when diluted. It is known that Zn2+ induces aggregation at concentrations lower than those observed with Zn2+-free insulin (Goldman, 1971; Fredericq, 1956) . Zn-insulin exists in the dimer form at concentrations of 16uM-insulin, whereas Zn2+-free insulin exists mainly as a monomer at this concentration (Goldman, 1971 ). In the studies described in this report it is not known whether Zn-insulin could exist as a dimer at the substantially lower concentrations of inhibitor (43.5 nM) used to inhibit 50 % ofthe insulin antibodies.
It is likely that the Zn-insulin complex is not essential for hormonal activity (Goldman & Carpenter, 1974) . However, the possibility that Zn2+ may modulate the action and turnover of insulin cannot be excluded. In most mammalian species, insulin is stored in the fl-cells as Zn crystals (Howell et al., 1969; Lazaris et al., 1974; Berglund & Hellman, 1976) . It is therefore likely to be secreted into the portal circulation and reach the liver within seconds in a Zn-insulin form. The degree to which such a Zn-insulin might influence degradation and binding by the liver is of significance with respect to the molecular action and turnover of insulin.
In preliminary experiments, it was possible to demonstrate that more l25l-labelled insulin was bound faster and its degradation inhibited in the livers of the Zn2+-treated mice than the Na+-treated mice Tarmas et al., 1977) . Thus there is a possibility that Zn-insulin will be metabolized and have molecular interactions different from Zn2+-free insulin in vivo.
